HCV NS-3 Serine protease inhibitors

摘要

Disclosed are compounds of the formula VI, which are inhibitors of the NS3 serine protease of the flavivirus HCV; wherein A is C(=O)OR1, or C(=O)NHSO2R2; p is independently 1 or 2; M is CR7R7'; Ru is H or C1-C3alkyl; q' is 0 or 1 and k is 0 to 3; Rz is H, or together with the asterisked carbon forms an olefinic bond; Rq is H or C1-C6alkyl; W is -CH2-, -O-, -C(=O)NH-, -OC(=O)-, -S-, -NH-, -NRa-, -NHSO2-, -NHC(=O)NH- or -NHC(=O)-, -NHC(=S)NH- or a bond; R8 is a ring system containing 1 or 2 saturated, partially saturated or unsaturated rings; Rx is H or C1-C5alkyl; or Rx is J; T is -CHR11- or -NRd-, where Rd is H, C1-C3alkyl or J; m is 0 or 1; n is 0 or 1; U is O or is absent; R15 and R16 are independently H, C1-C6alkyl, C0-C3alkylcarbocyclyl, C0-C3alkylheterocyclyl; G is -O-, -NRy-, -NRjNRj-; or a pharmaceutically acceptable salt thereof. Also disclosed is a pharmaceutical composition comprising a compound as defined above and a pharmaceutically acceptable carrier therefor, which may further comprise an additional HCV antiviral, selected from nucleoside analogue polymerase inhibitors, protease inhibitors, ribavirin and interferon.